While many GLP-1 drugs for the treatment for type 2 diabetes are currently available, this continues to be an attractive disease target for many of the biggest pharmaceutical players. Bristol-Myers Squibb and AstraZeneca market the GLP-1 agonists Byetta and Bydureon, and Novo Nordisk's Victoza is a leader in this specific class of drugs.
But wait -- it looks like another big pharma player is poised to enter this space. GlaxoSmithKline put its drug albiglutide forward for approval from the Food and Drug Administration last Monday and, pending approval, could grab part of this market. In this video, health care analysts Max Macaluso and David Williamson discuss what investors need to consider in this race to dominate the diabetes market.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Big Pharma Diabetes Face-Off originally appeared on Fool.com.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.